Abstract
Hepatitis C is one of the most common social diseases in the world. The improvements in both the early diagnostics of the hepatitis C and the treatment of acute viremia caused by hepatitis C virus are undoubtedly an urgent task. In present work, we offered the micro- and nanotraps for the capturing of HCV. As a capturing moiety, we designed and synthesized in E. coli a fusion protein consisting of large extracellular loop of CD81 receptor and streptavidin as spacing part. The obtained protein has been immobilized on the surface of PLA-based micro- and nanoparticles. The developed trapping systems were characterized in terms of their physico-chemical properties. In order to illustrate the ability of developed micro- and nanotraps to bind HCV, E2 core protein of HCV was synthesized as a fusion protein with GFP. Interaction of E2 protein and hepatitis C virus-mimicking particles with the developed trapping systems were testified by several methods.
Highlights
Production of the LEL CD81-SA Fusion Protein. As it was mentioned earlier, CD81 plays an important role in the attachment of the hepatitis C virus to the host cell through the interaction of protein large extracellular loop with the viral protein E2
In order to prepare trapping system capable of hepatitis C virus (HCV) binding, a recombinant LEL CD81 fusion protein with streptavidin was created as a receptor for immobilization onto the poly(lactic acid) (PLA) microparticles
The fusion protein consisted of LEL CD81 as capturing moiety for HCV and streptavidin as spacing part was designed and synthesized
Summary
The current treatment is based on administration of PEGylated alpha-interferon (PEG-IFN) and ribavirin (RBV)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
